HC Wainwright set a $8.00 price objective on Agile Therapeutics (NASDAQ:AGRX) in a report published on Friday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

“it as Just Another Delay; Reiterate Buy but Lower to $8 Stock Data 12/21/2017 Price $4.76 Exchange NASDAQ Price Target $8.00 52-Week High $6.62 52-Week Low $2.04 Enterprise Value (M) $131.3 Market Cap (M) $163 Shares Outstanding (M) 34.2 3 Month Avg Volume 267,948 Short Interest (M) 0.30 Balance Sheet Metrics Cash (M) $43.8 Total Debt (M) $12.1 Total Cash/Share $1.28 EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.27) (0.26)A (0.28) 2Q (0.29) (0.26)A (0.26) 3Q (0.27) (0.22)A (0.29) 4Q (0.18) (0.24) (0.32) FY (1.02) (0.98) (1.16) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 0.0 0.0A 0.0 2Q 0.0 0.0A 0.0 3Q 0.0 0.0A 0.0 4Q 0.0 0.0 0.0 FY 0.0 0.0 0.0 7 6 5 4 3 2 1 DEC- 16 APR- 17 AUG- 17 DEC- 17 20 15 10 5 0 Vol. (mil) Price Twirla Complete Response Letter surprisingly focused on patch adhesion; we believe the issues are readily addressable. The consensus investor Twirla sticking issue has been around the “high” Phase 3 Pearl Index (implied lower efficacy) vs. prior.”,” the firm’s analyst commented.

A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald restated a buy rating and issued a $8.00 price objective on shares of Agile Therapeutics in a report on Monday, November 20th. Royal Bank of Canada restated a buy rating and issued a $10.00 price objective on shares of Agile Therapeutics in a report on Wednesday, October 18th. Janney Montgomery Scott restated a buy rating and issued a $13.00 price objective on shares of Agile Therapeutics in a report on Thursday, September 7th. Finally, ValuEngine lowered shares of Agile Therapeutics from a sell rating to a strong sell rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Agile Therapeutics currently has a consensus rating of Buy and a consensus price target of $9.80.

Agile Therapeutics (NASDAQ AGRX) opened at $2.52 on Friday. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.14. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $6.70. The company has a market cap of $45.61, a P/E ratio of -2.74 and a beta of 2.02.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.03. sell-side analysts expect that Agile Therapeutics will post -0.99 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Alyeska Investment Group L.P. bought a new stake in Agile Therapeutics during the 3rd quarter valued at $3,747,000. Franklin Resources Inc. raised its holdings in Agile Therapeutics by 39.2% during the 2nd quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after buying an additional 780,578 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Agile Therapeutics during the 3rd quarter valued at $943,000. Caxton Corp raised its holdings in Agile Therapeutics by 12.1% during the 3rd quarter. Caxton Corp now owns 1,820,012 shares of the specialty pharmaceutical company’s stock valued at $8,117,000 after buying an additional 196,445 shares during the last quarter. Finally, Neuberger Berman Group LLC bought a new stake in Agile Therapeutics during the 3rd quarter valued at $613,000. Hedge funds and other institutional investors own 72.92% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2017/12/25/hc-wainwright-reiterates-8-00-price-target-for-agile-therapeutics-agrx.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.